News

Nymox Files For Marketing Approval For Fexapotide Triflutate in Europe

May 3, 2017:

May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.


Nymox Announces Private Placements of $2.24 Million

August 17, 2016:

August 17, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.


Nymox Announces Prostate Drug Progress

August 11, 2016:

August 11, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company’s Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.


Nymox Announces Change of Company’s Domicile and Head Office

August 4, 2015:

August 4, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.


Webcast

July 27, 2015:

July 27, 2015: To view the webcast, please click here


Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207)

July 27, 2015:

July 27, 2015: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.


Nymox Announces $850,000 Financing

June 16, 2015:

June 16, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.


Nymox Reports First Quarter 2015 Financial Results

May 15, 2015:

May 15, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.


Nymox Announces New Prostate Cancer Clinical Trial Results

April 20, 2015:

April 20, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today long-term clinical trial results from the Company’s NX-1207 prostate cancer study NX03-0040.


Nymox Announces Phase 3 BPH Studies

April 1, 2015:

April 1, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).